A Randomized placebo-controlled study of INCB018424, a selective janus kinase 1 & 2 (JAK1&2) inhibitor in rheumatoid arthritis (RA)

被引：0
|
作者：
Williams, William [1 ]
Scherle, Peggy [1 ]
Shi, Jack [1 ]
Newton, Robert [1 ]
McKeever, Edward [1 ]
Fridman, Jordan [1 ]
Burn, Timothy [1 ]
Vaddi, Kris [1 ]
Levy, Richard [1 ]
Moreland, Larry [2 ]
机构：
[1] Incyte Corp, Wilmington, DE USA
[2] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
来源：
ARTHRITIS AND RHEUMATISM | 2008年 / 58卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S431 / S431
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of topical INCB018424, a selective Janus kinase 1 & 2 (JAK1&2) inhibitor in psoriasis
    Punwani, Naresh
    Gottlieb, Alice
    Birnbaum, Jay
    Williarns, William
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2009, 60 (03) : AB176 - AB176
  • [2] Metabolism, Excretion, and Pharmacokinetics of [14C]INCB018424, a Selective Janus Tyrosine Kinase 1/2 Inhibitor, in Humans
    Shilling, Adam D.
    Nedza, Frank M.
    Emm, Thomas
    Diamond, Sharon
    McKeever, Edward
    Punwani, Naresh
    Williams, William
    Arvanitis, Argyrios
    Galya, Laurine G.
    Li, Mei
    Shepard, Stacey
    Rodgers, James
    Yue, Tai-Yuen
    Yeleswaram, Swamy
    [J]. DRUG METABOLISM AND DISPOSITION, 2010, 38 (11) : 2023 - 2031
  • [3] Discovery of INCB018424: A potent and selective JAK1/JAK2 inhibitor for the treatment of myeloproliferative neoplasms
    Rodgers, James D.
    Fridman, Jordan S.
    Shepard, S.
    Maduskuie, T. P.
    Arvanitis, A. G.
    Wang, H.
    Shao, L.
    Folmer, B.
    Falahatpisheh, N.
    Rafalski, M.
    Storace, L.
    Jalluri, R. K.
    Vaddi, K.
    Haley, P. J.
    Burn, T. C.
    Rupar, M.
    Liu, P. C.
    Covington, M. B.
    Caulder, E.
    Li, J.
    Waeltz, P.
    Margulis, A.
    Wynn, R.
    Becker-Pasha, M.
    Li, Y.
    Lo, Y.
    Thomas, B.
    Hollis, G.
    Favata, M. F.
    Wen, X.
    Kelly, J.
    Solomon, K.
    Scherle, P. A.
    Shi, J.
    Yeleswaram, S.
    Newton, R. C.
    Friedman, S. M.
    Metcalf, B.
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240
  • [4] Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis.
    Verstovsek, Srdan
    Kantarjian, Hagop
    Mesa, Ruben A.
    Pardanani, Animesh D.
    Cortes-Franco, Jorge
    Thomas, Deborah A.
    Estrov, Zeev
    Fridman, Jordan S.
    Bradley, Edward C.
    Erickson-Viitanen, Susan
    Vaddi, Kris
    Levy, Richard
    Tefferi, Ayalew
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (12): : 1117 - 1127
  • [5] Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
    Quintas-Cardama, Alfonso
    Vaddi, Kris
    Liu, Phillip
    Manshouri, Taghi
    Li, Jun
    Scherle, Peggy A.
    Caulder, Eian
    Wen, Xiaoming
    Li, Yanlong
    Waeltz, Paul
    Rupar, Mark
    Burn, Timothy
    Lo, Yvonne
    Kelley, Jennifer
    Covington, Maryanne
    Shepard, Stacey
    Rodgers, James D.
    Haley, Patrick
    Kantarjian, Hagop
    Fridman, Jordan S.
    Verstovsek, Srdan
    [J]. BLOOD, 2010, 115 (15) : 3109 - 3117
  • [6] Discovery and preclinical characterization of INCB018424, a selective JAK2 inhibitor for the treatment of myeloproliferative disorders
    Fridman, Jordan
    Nussenzveig, Roberto
    Liu, Phillip
    Rodgers, James
    Burn, Timothy
    Haley, Patrick
    Scherle, Peggy
    Newton, Robert
    Hollis, Gregory
    Friedman, Steven
    Verstovsek, Srdan
    Vaddi, Kris
    [J]. BLOOD, 2007, 110 (11) : 1035A - 1036A
  • [7] A Randomized, Dose-Ranging, Placebo-Controlled, 84-Day Study Of INCB039110, a Selective Janus Kinase-1 Inhibitor, In Patients With Active Rheumatoid Arthritis
    Luchi, Monica
    Fidelus-Gort, Rosanne
    Douglas, Diane
    Zhang, Haifeng
    Flores, Robert
    Newton, Robert
    Scherle, Peggy
    Yeleswaram, Swamy
    Chen, Xuejun
    Sandor, Victor
    [J]. ARTHRITIS AND RHEUMATISM, 2013, 65 : S765 - S766
  • [8] The Clinical Phenotype of Myelofibrosis Encompasses a Chronic Inflammatory State That Is Favorably Altered by INCB018424, a Selective Inhibitor of JAK1/2
    Tefferi, Ayalew
    Kantarjian, Hagop M.
    Pardanani, Animesh D.
    Mesa, Ruben A.
    Newton, Robert C.
    Scherle, Peggy A.
    Burn, Timothy
    Verstovsek, Srdan
    [J]. BLOOD, 2008, 112 (11) : 968 - 969
  • [9] INCB018424, a Selective JAK1/2 Inhibitor, Significantly Improves the Compromised Nutritional Status and Frank Cachexia in Patients with Myelofibrosis (MF)
    Mesa, Ruben A.
    Verstovsek, Srdan
    Kantarjian, Hagop M.
    Pardanani, Animesh D.
    Friedman, Steven
    Newton, Robert
    Erickson-Viitanen, Susan
    Hunter, Deborah
    Redman, John
    Yeleswaram, Swamy
    Bradley, Edward
    Tefferi, Ayalew
    [J]. BLOOD, 2008, 112 (11) : 621 - 622
  • [10] A randomized, placebo-controlled, phase 2 study of the Janus Kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa
    Alavi, Afsaneh
    Hamzavi, Iltefat
    Brown, Kurt
    Santos, Leandro L.
    Zhu, Zhaoyin
    Howell, Michael D.
    Kirby, Joslyn
    [J]. EXPERIMENTAL DERMATOLOGY, 2021, 30 : 69 - 70
12345